Sunday, 24 November 2024
  
Login

Australia's most trusted
source of pharma news

Sunday, 24 November 2024
News

Blockbuster-to-be off to a slow start

Posted 9 May 2023 AM

The race-car start expected to have come with the listing of Roche's blockbuster-to-be, Vabysmo, has not eventuated with the eye drug pulling in a smidgen under $10 million in its first quarter.

The much anticipated medication was expected to quickly take market share from Bayer's Eylea - long the most-reimbursed drug on the PBS - and Novartis' top-seller Lucentis.

To see the whole article, please login

Popular

Top pharmas for women revealed
$80K fine for Aussie Code Breach
Who's trying to dethrone Keytruda?
Senior leaders moving on and up
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home